WO2017158151A1 - Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale - Google Patents
Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale Download PDFInfo
- Publication number
- WO2017158151A1 WO2017158151A1 PCT/EP2017/056361 EP2017056361W WO2017158151A1 WO 2017158151 A1 WO2017158151 A1 WO 2017158151A1 EP 2017056361 W EP2017056361 W EP 2017056361W WO 2017158151 A1 WO2017158151 A1 WO 2017158151A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- methyl
- title compound
- alkyl
- mmol
- Prior art date
Links
- 0 CC1(*)C=CC(C2(CCCCC2)C=N)=CC=C1 Chemical compound CC1(*)C=CC(C2(CCCCC2)C=N)=CC=C1 0.000 description 16
- HKRBXIQWMMZYFB-IBGZPJMESA-N CC(C)N([C@@H](C)CN(C(CC1(CCCCC1)c1cc(C)cc(C)c1)=NC1=O)C2=C1O)C2=O Chemical compound CC(C)N([C@@H](C)CN(C(CC1(CCCCC1)c1cc(C)cc(C)c1)=NC1=O)C2=C1O)C2=O HKRBXIQWMMZYFB-IBGZPJMESA-N 0.000 description 1
- NFBPGHNNCIFUSN-UHFFFAOYSA-N CC(CN(C(CC1(CCCC1)c1cc(C)cc(C)c1)=NC1=O)C2=C1O)N(C1CC1)C2=O Chemical compound CC(CN(C(CC1(CCCC1)c1cc(C)cc(C)c1)=NC1=O)C2=C1O)N(C1CC1)C2=O NFBPGHNNCIFUSN-UHFFFAOYSA-N 0.000 description 1
- OPHLCYORULWEAL-UHFFFAOYSA-N CC(CN(C(CC1(CCCC1)c1ccccc1)=NC1=O)C2=C1O)N(C)C2=O Chemical compound CC(CN(C(CC1(CCCC1)c1ccccc1)=NC1=O)C2=C1O)N(C)C2=O OPHLCYORULWEAL-UHFFFAOYSA-N 0.000 description 1
- QHIMBMWDVUCZQL-GZWBLTSWSA-N CCC(CC(N(C[C@H](C)N(C)C1=O)C1=C1O)=NC1=O)(COC)c1cc(C)cc(C)c1 Chemical compound CCC(CC(N(C[C@H](C)N(C)C1=O)C1=C1O)=NC1=O)(COC)c1cc(C)cc(C)c1 QHIMBMWDVUCZQL-GZWBLTSWSA-N 0.000 description 1
- KYCAETSSSCDLFW-UHFFFAOYSA-N CCc(cccc1C2(CO)CCCC2)c1F Chemical compound CCc(cccc1C2(CO)CCCC2)c1F KYCAETSSSCDLFW-UHFFFAOYSA-N 0.000 description 1
- FQMQZJJBRDOVLU-UHFFFAOYSA-N CCc1cc(C2(CC(N(CCN(C)C3=O)C3=C3OCc4ccccc4)=NC3=O)CCCC2)ccc1 Chemical compound CCc1cc(C2(CC(N(CCN(C)C3=O)C3=C3OCc4ccccc4)=NC3=O)CCCC2)ccc1 FQMQZJJBRDOVLU-UHFFFAOYSA-N 0.000 description 1
- SYKCMVWLFBUWRQ-AWEZNQCLSA-N CCc1cc(C2(CC(N(C[C@H](C)N(C)C3=O)C3=C3O)=NC3=[O-])CCCC2)ccc1F Chemical compound CCc1cc(C2(CC(N(C[C@H](C)N(C)C3=O)C3=C3O)=NC3=[O-])CCCC2)ccc1F SYKCMVWLFBUWRQ-AWEZNQCLSA-N 0.000 description 1
- ATCBGIHGRDRLNT-INIZCTEOSA-N CCc1cc(C2(CC(N(C[C@H](C)N(CC(NC)=O)C3=O)C3=C3O)=NC3=O)CCCC2)ccc1 Chemical compound CCc1cc(C2(CC(N(C[C@H](C)N(CC(NC)=O)C3=O)C3=C3O)=NC3=O)CCCC2)ccc1 ATCBGIHGRDRLNT-INIZCTEOSA-N 0.000 description 1
- SPOOOGREBUWXKB-GOSISDBHSA-N CCc1cc(C2(CC(N(C[C@H](CSC)N(C)C3=[O-])C3=C3O)=NC3=O)CCCC2)ccc1 Chemical compound CCc1cc(C2(CC(N(C[C@H](CSC)N(C)C3=[O-])C3=C3O)=NC3=O)CCCC2)ccc1 SPOOOGREBUWXKB-GOSISDBHSA-N 0.000 description 1
- RJDVEKNEOOTHJZ-QHCPKHFHSA-N CCc1cccc(C2(CC(NC(C(N(C(C)C)[C@@H](C)CO)=O)=C3OCc4ccccc4)=NC3=O)CCCC2)c1 Chemical compound CCc1cccc(C2(CC(NC(C(N(C(C)C)[C@@H](C)CO)=O)=C3OCc4ccccc4)=NC3=O)CCCC2)c1 RJDVEKNEOOTHJZ-QHCPKHFHSA-N 0.000 description 1
- VTCLGVZLLTULTF-KRWDZBQOSA-N CN([C@@H](CCOC)CN(C(CC1(CCCC1)c1ccccc1)=NC1=O)C2=C1O)C2=O Chemical compound CN([C@@H](CCOC)CN(C(CC1(CCCC1)c1ccccc1)=NC1=O)C2=C1O)C2=O VTCLGVZLLTULTF-KRWDZBQOSA-N 0.000 description 1
- VTCLGVZLLTULTF-QGZVFWFLSA-N CN([C@H](CCOC)CN(C(CC1(CCCC1)c1ccccc1)=NC1=O)C2=C1O)C2=O Chemical compound CN([C@H](CCOC)CN(C(CC1(CCCC1)c1ccccc1)=NC1=O)C2=C1O)C2=O VTCLGVZLLTULTF-QGZVFWFLSA-N 0.000 description 1
- TVZCVAUHJZEOME-UGHUOPPNSA-N C[C@@H](CN(C(CC(CCCC1)(C1OCc1ccccc1)c(cc1)ccc1Cl)=NC1=O)C2=C1O)N(C)C2=O Chemical compound C[C@@H](CN(C(CC(CCCC1)(C1OCc1ccccc1)c(cc1)ccc1Cl)=NC1=O)C2=C1O)N(C)C2=O TVZCVAUHJZEOME-UGHUOPPNSA-N 0.000 description 1
- BKNUMTHLSJGGQT-AWEZNQCLSA-N C[C@@H](CN(C(CC1(CCCC1)c1cc(C)cc(Cl)c1)=NC1=O)C2=C1O)N(C)C2=O Chemical compound C[C@@H](CN(C(CC1(CCCC1)c1cc(C)cc(Cl)c1)=NC1=O)C2=C1O)N(C)C2=O BKNUMTHLSJGGQT-AWEZNQCLSA-N 0.000 description 1
- IFMNNXWOFBUBSO-HNNXBMFYSA-N C[C@@H](CN(C(CC1(CCCC1)c1cc(CCF)ccc1)=NC1=O)C2=C1O)N(C)C2=O Chemical compound C[C@@H](CN(C(CC1(CCCC1)c1cc(CCF)ccc1)=NC1=O)C2=C1O)N(C)C2=O IFMNNXWOFBUBSO-HNNXBMFYSA-N 0.000 description 1
- QZVRNTAQNAVUHC-AWEZNQCLSA-N C[C@@H](CN(C(CC1(CCCCC1)c1cccc(Br)c1)=NC1=O)C2=C1O)N(C)C2=O Chemical compound C[C@@H](CN(C(CC1(CCCCC1)c1cccc(Br)c1)=NC1=O)C2=C1O)N(C)C2=O QZVRNTAQNAVUHC-AWEZNQCLSA-N 0.000 description 1
- PGQVKMILOGMPOT-XKRZFCRKSA-O C[C@@H](CNC1)N(C(/C=C\NC)=[NH2+])C1=O Chemical compound C[C@@H](CNC1)N(C(/C=C\NC)=[NH2+])C1=O PGQVKMILOGMPOT-XKRZFCRKSA-O 0.000 description 1
- YRJWVKVJWADQTE-IBGZPJMESA-N Cc1cc(C)cc(C2(CC(N(C[C@H](CCSC)N(C)C3=O)C3=C3O)=NC3=O)CCCC2)c1 Chemical compound Cc1cc(C)cc(C2(CC(N(C[C@H](CCSC)N(C)C3=O)C3=C3O)=NC3=O)CCCC2)c1 YRJWVKVJWADQTE-IBGZPJMESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
La présente invention concerne un composé de formule générale (I), se présentant éventuellement sous la forme d'un sel, d'un solvate, d'un polymorphe, d'un comédicament, d'un cocristal, d'un promédicament, d'un tautomère, d'un racémate, d'un énantiomère ou d'un diastéréomère pharmaceutiquement acceptable, ou bien d'un mélange de ceux-ci, utiles pour traiter, soulager ou prévenir une maladie virale, en particulier la grippe.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16161197.5 | 2016-03-18 | ||
EP16161197 | 2016-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017158151A1 true WO2017158151A1 (fr) | 2017-09-21 |
Family
ID=55587155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/056361 WO2017158151A1 (fr) | 2016-03-18 | 2017-03-17 | Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017158151A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180118760A1 (en) | 2015-04-28 | 2018-05-03 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivatives and prodrugs thereof |
US10759814B2 (en) | 2016-08-10 | 2020-09-01 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
US11040048B2 (en) | 2015-12-15 | 2021-06-22 | Shionogi & Co., Ltd. | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004713A1 (fr) | 1993-08-06 | 1995-02-16 | The Upjohn Company | 2-aminoindanes utilises comme ligands selectifs de la dopamine d3 |
US20030045520A1 (en) | 1999-06-30 | 2003-03-06 | Hidemitsu Nishida | Tricyclic compound having spiro union |
WO2003097637A1 (fr) | 2002-05-16 | 2003-11-27 | F. Hoffmann-La Roche Ag | (imidazol-1-yl-methyl)-pyridazine en tant qu'antagoniste du recepteur nmda |
WO2005087766A1 (fr) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Inhibiteurs de l'intégrase du vih |
WO2005100365A1 (fr) | 2004-04-12 | 2005-10-27 | Sankyo Company, Limited | Derivés de thienopyridine |
US20070072831A1 (en) | 2005-05-16 | 2007-03-29 | Gilead Sciences, Inc. | Integrase inhibitor compounds |
WO2009005674A2 (fr) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Nouveaux inhibiteurs de la transcriptase inverse du vih |
WO2009087127A1 (fr) | 2008-01-11 | 2009-07-16 | F. Hoffmann-La Roche Ag | Modulateurs pour l'amyloïde-bêta |
WO2010147068A1 (fr) | 2009-06-15 | 2010-12-23 | 塩野義製薬株式会社 | Dérivé de carbamoylpyridone polycyclique substituée |
WO2012039414A1 (fr) | 2010-09-24 | 2012-03-29 | 塩野義製薬株式会社 | Promédicament dérivé de carbamoylpyridone polycyclique substituée |
US20140194431A1 (en) | 2013-01-08 | 2014-07-10 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
-
2017
- 2017-03-17 WO PCT/EP2017/056361 patent/WO2017158151A1/fr active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004713A1 (fr) | 1993-08-06 | 1995-02-16 | The Upjohn Company | 2-aminoindanes utilises comme ligands selectifs de la dopamine d3 |
US20030045520A1 (en) | 1999-06-30 | 2003-03-06 | Hidemitsu Nishida | Tricyclic compound having spiro union |
WO2003097637A1 (fr) | 2002-05-16 | 2003-11-27 | F. Hoffmann-La Roche Ag | (imidazol-1-yl-methyl)-pyridazine en tant qu'antagoniste du recepteur nmda |
WO2005087766A1 (fr) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Inhibiteurs de l'intégrase du vih |
WO2005100365A1 (fr) | 2004-04-12 | 2005-10-27 | Sankyo Company, Limited | Derivés de thienopyridine |
US20070072831A1 (en) | 2005-05-16 | 2007-03-29 | Gilead Sciences, Inc. | Integrase inhibitor compounds |
WO2009005674A2 (fr) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Nouveaux inhibiteurs de la transcriptase inverse du vih |
WO2009087127A1 (fr) | 2008-01-11 | 2009-07-16 | F. Hoffmann-La Roche Ag | Modulateurs pour l'amyloïde-bêta |
WO2010147068A1 (fr) | 2009-06-15 | 2010-12-23 | 塩野義製薬株式会社 | Dérivé de carbamoylpyridone polycyclique substituée |
WO2012039414A1 (fr) | 2010-09-24 | 2012-03-29 | 塩野義製薬株式会社 | Promédicament dérivé de carbamoylpyridone polycyclique substituée |
US20140194431A1 (en) | 2013-01-08 | 2014-07-10 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
WO2014108406A1 (fr) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale |
Non-Patent Citations (21)
Title |
---|
D. J. GOOD ET AL., CRYST. GROWTH DES., vol. 9, no. 5, 2009, pages 2252 - 2264 |
DHARAN ET AL., THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 301, no. 10, 2009, pages 1034 - 1041 |
DIAS ET AL., NATURE, vol. 458, 2009, pages 914 - 918 |
ERIKSSON ET AL., ANTIMICROB. AGENTS CHEMOTHER, vol. 11, 1977, pages 946 - 951 |
FODOR, ACTA VIROFOGICA, vol. 57, 2013, pages 113 - 122 |
FURUTA ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, pages 981 - 986 |
GUILLIGAY ET AL., NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 15, no. 5, 2008, pages 500 - 506 |
LEUENBERGER, H.G.W, NAGEL, B. AND KÖLBL, H.: "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", 1995, HELVETICA CHIMICA ACTA |
MAGDEN ET AL., APPL. MICROBIOL. BIOTECHNOL., vol. 66, 2005, pages 612 - 621 |
MAGDEN, APPI. MICROBIO!. BIOTECHNOL, vol. 66, 2005, pages 612 - 621 |
MOSCONA ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, no. 10, 2009, pages 953 - 956 |
N. DAS ET AL., EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 41, 2010, pages 571 - 588 |
NEUMANN ET AL., NATURE, vol. 459, no. 7249, 18 December 2008 (2008-12-18), pages 931 - 939 |
NING SHAN ET AL., DRUG DISCOVERY TODAY, vol. 13, no. 9/10, 2008, pages 440 - 446 |
PROG. MED., vol. 5, 1985, pages 2157 - 2161 |
RUI SHANG ET AL., ANGEW. CHEM. INT. ED., vol. 50, 2011, pages 4470 - 4474 |
S. M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104 |
SZRETTER KJ; BALISH AL; KATZ JM: "Curr Protoc Microbiol.", December 2006, article "Unit 15G.1. Influenza: propagation, quantification, and storage" |
TISDALE ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 2454 - 2458 |
TOMASSINI ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 40, 1996, pages 1189 - 1193 |
VON ITZSTEIN ET AL., NATURE, vol. 363, 1993, pages 418 - 423 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180118760A1 (en) | 2015-04-28 | 2018-05-03 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivatives and prodrugs thereof |
US10392406B2 (en) | 2015-04-28 | 2019-08-27 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivatives and prodrugs thereof |
US11040048B2 (en) | 2015-12-15 | 2021-06-22 | Shionogi & Co., Ltd. | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug |
US10759814B2 (en) | 2016-08-10 | 2020-09-01 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
US11306106B2 (en) | 2016-08-10 | 2022-04-19 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9988390B2 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
US9045486B2 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
AU2012204982B2 (en) | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | |
WO2017096301A1 (fr) | Inhibiteurs dérivés d'isoxazolidine de protéine kinase 1 interagissant avec un récepteur (ripk 1) | |
TWI803467B (zh) | 用於治療正黏液病毒感染之稠合三環噠嗪酮化合物 | |
IL268004A (en) | History of tyrosine amide as RHO-kinase inhibitors | |
WO2017133667A1 (fr) | Dérivés de pyrimidine et de pyridine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes | |
JP2019512485A (ja) | オルトミクソウイルス感染の処置に有用な三環式化合物 | |
WO2017133670A1 (fr) | Dérivés de pyridine et de pyrimidine et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe | |
KR20150009553A (ko) | 7-옥소-티아졸로피리딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도 | |
KR102254837B1 (ko) | 호흡기 합포체 바이러스의 항바이러스제로서의 퀴녹살리논 및 디하이드로퀴녹살리논 | |
WO2017133664A1 (fr) | Dérivés bicycliques de pyridine et de pyrimidine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes | |
KR20150014506A (ko) | 바이러스성 질환의 치료, 개선 또는 예방에서 유용한 7-옥소-4,7-디하이드로-피라졸로[1,5-a]피리미딘 유도체 | |
AU2016272258A1 (en) | Pyrido(3,4-d)pyrimidine derivative and pharmaceutically acceptable salt thereof | |
NZ522732A (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
TW200936589A (en) | Substituted arylamide diazepinopyrimidone derivatives | |
US11014882B2 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
WO2017133665A1 (fr) | Dérivés de 6,7-diazaindazole et de 6,7-diazaindole et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe | |
WO2017109088A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale | |
WO2017158151A1 (fr) | Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale | |
WO2014164756A1 (fr) | Nouveaux modulateurs de l'activité du récepteur 7 de la 5-hydroxytryptamine et leur procédé d'utilisation | |
WO2017133669A1 (fr) | Dérivés 5,7-diazaindole et 5,7-diazaindazole et leur utilisation pour traiter, atténuer ou prévenir la grippe | |
WO2017133658A1 (fr) | Dérivés de 4,7-diazaindole et 4,7-diazaindazole et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes | |
CN108727369B (zh) | 流感病毒复制抑制剂及其用途 | |
JP2024033009A (ja) | インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての10-(ジ(フェニル)メチル)-4-ヒドロキシ-8,9,9a,10-テトラヒドロ-7H-ピロロ[1’,2’:4,5]ピラジノ[1,2-b]ピリダジン-3,5-ジオン誘導体および関連化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17716801 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15/01/2019) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17716801 Country of ref document: EP Kind code of ref document: A1 |